Stay updated on Vodobatinib for Ph+ CML: Safety & Efficacy Clinical Trial
Sign up to get notified when there's something new on the Vodobatinib for Ph+ CML: Safety & Efficacy Clinical Trial page.

Latest updates to the Vodobatinib for Ph+ CML: Safety & Efficacy Clinical Trial page
- Check2 days agoChange DetectedThe page history now includes a newer revision tag, v3.6.2, and the older tag, v3.6.0, is removed, indicating an update to the study record's revision history.SummaryDifference0.1%

- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedRecord history now indicates that the study is no longer looking for participants, signaling that enrollment has ceased. The entry also updates the record version to v3.6.0, replacing the previous v3.5.5.SummaryDifference0.4%

- Check23 days agoChange DetectedThe page shows a new software revision label, updating from v3.5.4 to v3.5.5. This indicates a platform-level release for the history view rather than changes to the study record itself.SummaryDifference0.1%

- Check45 days agoChange DetectedRecord History now includes an administrative closure and termination, with new entries indicating Results Posted and updated study sections. Added sections cover Adverse Events, Baseline Characteristics, Outcome Measures, Participant Flow, and other core documentation.SummaryDifference2%

- Check59 days agoChange DetectedThe Record History now includes a new revision entry (v3.5.3) and removes the prior revision (v3.5.2). This reflects an update to the study record's revision metadata.SummaryDifference0.1%

- Check66 days agoChange DetectedThe number of “Results Submission Events” shown in the record history increased from 3 to 4, reflecting an additional results-submission event entry. This does not indicate a change to the substantive study details themselves.SummaryDifference0.1%

Stay in the know with updates to Vodobatinib for Ph+ CML: Safety & Efficacy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Vodobatinib for Ph+ CML: Safety & Efficacy Clinical Trial page.